Subscribe To
Davita clinical research to present new findings at american society of nephrology kidney week 2021
DENVER, Nov. 4, 2021 /PRNewswire/ -- DaVita Clinical Research (DCR) will present eight research abstracts from company representatives and medical pr...
November 4, 2021, 6:04 am
Davita clinical research to present new findings at american society of nephrology kidney week 2021
DENVER, Nov. 4, 2021 /PRNewswire/ -- DaVita Clinical Research (DCR) will present eight research abstracts from company representatives and medical pr...
November 4, 2021, 6:04 am
Repare therapeutics issues statement regarding inadvertent issuance of phase 1/2 tresr rp-3500 clinical trial abstract by the aacr-nci-eortc virtual international conference
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...
October 7, 2021, 5:08 pm
Repare therapeutics issues statement regarding inadvertent issuance of phase 1/2 tresr rp-3500 clinical trial abstract by the aacr-nci-eortc virtual international conference
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...
October 7, 2021, 5:08 pm
Repare therapeutics issues statement regarding inadvertent issuance of phase 1/2 tresr rp-3500 clinical trial abstract by the aacr-nci-eortc virtual international conference
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...
October 7, 2021, 5:08 pm
Cytosorbents announces availability of preliminary data abstracts from two endocarditis studies, including the remove study, to be presented at the eacts conference
MONMOUTH JUNCTION, N.J., Oct. 7, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening condi...
October 7, 2021, 3:11 pm
Cytosorbents announces availability of preliminary data abstracts from two endocarditis studies, including the remove study, to be presented at the eacts conference
MONMOUTH JUNCTION, N.J., Oct. 7, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening condi...
October 7, 2021, 3:11 pm
Cytosorbents announces availability of preliminary data abstracts from two endocarditis studies, including the remove study, to be presented at the eacts conference
MONMOUTH JUNCTION, N.J., Oct. 7, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening condi...
October 7, 2021, 3:11 pm
Natera announces completion of the largest prospective validation study of a commercial cell-free dna test in lung transplantation
AUSTIN, Texas, Oct. 6, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in improving patient outcomes through genetic and cell-free DNA (cf...
October 6, 2021, 8:33 am
Natera announces completion of the largest prospective validation study of a commercial cell-free dna test in lung transplantation
AUSTIN, Texas, Oct. 6, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in improving patient outcomes through genetic and cell-free DNA (cf...
October 6, 2021, 8:33 am
Natera announces completion of the largest prospective validation study of a commercial cell-free dna test in lung transplantation
AUSTIN, Texas, Oct. 6, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in improving patient outcomes through genetic and cell-free DNA (cf...
October 6, 2021, 8:33 am
Genentech to present new data on ocrevus (ocrelizumab) in multiple sclerosis and enspryng (satralizumab-mwge) in neuromyelitis optica spectrum disorder at ectrims 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus® ...
October 5, 2021, 1:00 am
Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...
October 5, 2021, 1:00 am
Genentech to present new data on ocrevus (ocrelizumab) in multiple sclerosis and enspryng (satralizumab-mwge) in neuromyelitis optica spectrum disorder at ectrims 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus® ...
October 5, 2021, 1:00 am
Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...
October 5, 2021, 1:00 am
Genentech to present new data on ocrevus (ocrelizumab) in multiple sclerosis and enspryng (satralizumab-mwge) in neuromyelitis optica spectrum disorder at ectrims 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus® ...
October 5, 2021, 1:00 am
Roche to present new data on ocrevus in multiple sclerosis and enspryng in neuromyelitis optica spectrum disorder at ectrims 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be...
October 5, 2021, 1:00 am
Genentech to present new data on ocrevus (ocrelizumab) in multiple sclerosis and enspryng (satralizumab-mwge) in neuromyelitis optica spectrum disorder at ectrims 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus® ...
October 5, 2021, 1:00 am
Genentech to present new data on ocrevus (ocrelizumab) in multiple sclerosis and enspryng (satralizumab-mwge) in neuromyelitis optica spectrum disorder at ectrims 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus® ...
October 5, 2021, 1:00 am
Genentech to present new data on ocrevus (ocrelizumab) in multiple sclerosis and enspryng (satralizumab-mwge) in neuromyelitis optica spectrum disorder at ectrims 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new Ocrevus® ...
October 5, 2021, 1:00 am